Chemical: Drug
tetrabenazine
PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.
Annotated Labels
- Annotation of FDA Label for tetrabenazine and CYP2D6
- Annotation of PMDA Label for tetrabenazine and CYP2D6
- Annotation of HCSC Label for tetrabenazine and CYP2D6
1. Annotation of FDA Label for tetrabenazine and CYP2D6
Summary
Tetrabenazine is used to treat Huntington's Disease chorea. Its primary metabolites are metabolized mainly by CYP2D6. Patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM). People with CYP2D6 poor metabolizer genotypes should be treated with lower doses.
There's more of this label. Read more.
2. Annotation of PMDA Label for tetrabenazine and CYP2D6
Summary
The PMDA package insert for tetrabenazine states that CYP2D6 poor metabolizers and intermediate metabolizer are at increased risk of developing side effects due to higher levels of the active metabolite, and that caution should be used in treating these patients.
There's more of this label. Read more.
3. Annotation of HCSC Label for tetrabenazine and CYP2D6
Summary
The product monograph for tetrabenazine notes that the tetrabenazine active metabolite HTBZ is likely increased in CYP2D6 poor metabolizers as compared to extensive metabolizers, and that caution in dosing should be exercised.
There's more of this label. Read more.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
Overview
- Tetra benazin
- Tetrabenazina [inn-spanish]
- Tetrabenazinum [inn-latin]
- Tetrabenzaine
- Tetrabenzine
- Nitoman
- Regulin
- Rubigen
- Xenazine
PharmGKB Accession Id
PA140222719
Type(s):
Drug
Description
Source: Drug Bank
Other Vocabularies
- ATC: Other nervous system drugs (N07XX)
- UMLS: Tetrabenazine (C0039623)
- RxNorm: Tetrabenazine (10390)
- NDFRT: TETRABENAZINE (N0000177920)
Information pulled from DrugBank has not been reviewed by PharmGKB.
Pharmacology, Interactions, and Contraindications
Mechanism of Action
Source: Drug Bank
Absorption, Distribution, Metabolism, Elimination & Toxicity
Route of Elimination
Source: Drug Bank
Chemical Properties
SMILES
CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
Source: PubChem
InChI String
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
Source: PubChem
Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.
Curated Information ?
Drug Targets
| Gene | Description |
|---|---|
| SLC18A2 | (source: Drug Bank ) |
Curated Information ?
Publications related to tetrabenazine: 34
LinkOuts
- Web Resource:
- Wikipedia
- National Drug Code Directory:
- 67386-421-01
- DrugBank:
- DB04844
- Drugs Product Database (DPD):
- 2199270
- BindingDB:
- 50017701
- ChemSpider:
- 5796
- Therapeutic Targets Database:
- DAP000756
- FDA Drug Label at DailyMed:
- ac768bab-8afa-4446-bc7f-caeeffec0cda
Clinical Trials
These are trials that mention tetrabenazine and are related to either pharmacogenetics or pharmacogenomics.
NURSA Datasets
No NURSA datasets available.